Penetration-enhancing composition comprising ionic liquids and sponge spicules, active composition comprising penetration-enhancing composition, and uses
By combining bioactive ionic liquids and sponge bone needles, the problems of low solubility of insoluble drugs in skin administration and high toxicity and cost of traditional osmotic promotion techniques are solved, and efficient percutaneous absorption and green administration are achieved.
Patent Information
- Application Number
- PCT/CN2024/092200
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-14
AI Technical Summary
Among the existing skin drug delivery technologies, the solubility of insoluble drugs is low and the traditional solvent is highly toxic. The existing osmotic technology has no significant effect on lipophilic insoluble drugs. The physical osmotic method and equipment requirements are high, the cost is high, and the chemical can promote Low biocompatibility of penetrants.
The composition of bioactive ionic liquid and sponge bone needle is used to improve the solubility of insoluble active ingredients through the ionic liquid, and a microchannel is used to form on the skin to achieve effective percutaneous absorption of insoluble drugs.
It improves the solubility and percutaneous absorption efficiency of insoluble active ingredients, provides a green, biofriendly route of administration, reduces the toxicity risk of traditional solvents, and reduces the equipment requirements and costs of physical osmotic proliferation methods.
Smart Images

Figure CN2024092200_14112024_PF_FP_ABST
Abstract
Description
Penetration-promoting composition of ionic liquid and sponge spicule, active composition and application thereof
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority based on the Chinese patent application filed with the State Intellectual Property Office of China on May 11, 2023, with application number: 2023105280614, and the name of the invention: "Penetration-enhancing composition of ionic liquid and sponge bone needle and its active composition and application". The content of the Chinese patent application is hereby introduced into the text of this application. Technical Field
[0003] The invention belongs to the field of pharmaceutical technology, and in particular relates to a skin drug delivery technology. Background Art
[0004] Incorporating poorly soluble drugs into drug delivery systems remains a challenge in the pharmaceutical and cosmetic industries. Furthermore, the low solubility of drugs is becoming increasingly prominent in the development and application of new chemical entities (NCEs), with approximately 40% of developed NCEs being poorly soluble in water. While traditional polar organic solvents, such as pyridine, N,N-dimethylformamide (DMF), and dimethyl sulfoxide (DMSO), can increase the solubility of poorly soluble drugs, they are not suitable for use in drug delivery systems due to their volatility, flammability, and toxicity. Given these limitations of polar organic solvents, it is crucial to identify promising green solvents to increase the solubility of poorly soluble drugs.
[0005] Ionic liquids (ILs), also known as room-temperature molten salts, are organic salts composed of organic cations and organic or inorganic anions that are liquid at room temperature. Compared to traditional organic solvents, ILs are nonvolatile, nonflammable, low in toxicity, and stable. They also have good solubility for many inorganic salts and organic compounds. Furthermore, a variety of cations and anions can be used to design and synthesize ILs to meet specific requirements. Therefore, ILs are considered a green alternative solvent for drug delivery systems. However, commonly used ILs are typically synthesized from petroleum-derived compounds through quaternization reactions. They are non-biodegradable and highly toxic to the environment and organisms, making them less environmentally friendly and biofriendly than anticipated. Against this backdrop, the development of biocompatible ILs has been a focus of intensive research. Their synthesis from renewable, bio-derived natural compounds has resulted in the development of novel bioactive ionic liquids (Bio-ILs) with enhanced toxicological profiles and biodegradability. In the past few years, research has focused on the use of choline as the cationic moiety in the structure of bioactive ILs, resulting in a large family of choline-based ILs. However, in addition to the well-studied choline-based ionic liquids, there are many natural compounds with biological activity extracted from organisms in nature that can be used as raw materials for the synthesis of Bio-ILs and are in urgent need of development.
[0006] The skin, the largest organ in the human body, provides a direct route for therapeutic drug delivery. Compared to oral and parenteral administration, transdermal drug delivery offers the advantages of ease of administration, avoids drug breakdown in the gastrointestinal tract and first-pass effects in the liver, and can also alleviate pain and improve patient compliance. These characteristics have garnered significant attention for transdermal drug delivery. However, due to the classic "brick and mortar" structure of the skin's outermost layer, the stratum corneum, while serving as a highly defensive barrier against the external environment, protecting the body from toxic chemicals and pathogenic microorganisms, it also hinders the transdermal delivery of drugs within transdermal drug delivery systems. To break down the skin barrier, a range of penetration-enhancing methods have been applied to transdermal drug delivery systems. Common methods include microneedle technology, chemical penetration enhancers, low-frequency ultrasound technology, skin-penetrating peptides, electroporation technology, iontophoresis technology, and nanoliposome systems. However, these existing skin penetration enhancement technologies, such as iontophoresis, are only applicable to ionic drugs and have no significant penetration-enhancing effect on lipophilic substances and uncharged drugs. Physical penetration enhancement methods such as low-frequency ultrasound, electroporation, and microneedles have high requirements for instruments and equipment, high production costs, and limited scope of use. Traditional chemical penetration enhancers have low biocompatibility, high irritation, and relatively limited penetration-enhancing effects.
[0007] Sponge spicules refer to the skeleton of a multicellular biological sponge that grows in seawater or freshwater environments. Most of them are siliceous, and a small number are calcareous. Spiules have various morphological structures, including uniaxial, biaxial, triaxial and multiaxial. Some uniaxial sponge spicules are uniform in size and have sharp tips. This feature is very suitable for use as a new type of biological microneedle material in the field of skin penetration enhancement. Compared with microneedle technology, it has more advantages, such as controllable dosage, adjustable strength, flexible usage and usage area, can be applied to different parts of the skin, and can be retained in the skin stratum corneum for a long time and form a large number of persistent microchannels, thereby better promoting the transdermal absorption of drug molecules. However, when sponge spicules are used alone to deliver drug molecules, the penetration enhancement effect will drop sharply, and the skin channels opened by sponge spicules are hydrophilic, which makes it difficult to use this approach for lipophilic and poorly soluble drugs. Therefore, the purpose of this invention is to develop a more effective penetration enhancement approach for poorly soluble drugs.
[0008] Summary of the Invention
[0009] The present invention aims to overcome the shortcomings of the prior art and provides a penetration-enhancing composition of an ionic liquid and sponge spicules, as well as its active composition and application. The present invention combines the ionic liquid with the sponge spicules to overcome the barrier effect of the skin's stratum corneum while utilizing the synergistic effect of the ionic liquid and sponge spicules to effectively increase the transdermal absorption of poorly soluble active ingredients.
[0010] One of the technical solutions adopted by the present invention to solve the technical problem is:
[0011] A penetration-promoting composition comprises sponge spicules and ionic liquid.
[0012] In a specific embodiment, the penetration-enhancing composition consists of the sponge spicules and the ionic liquid.
[0013] Preferably, the sponge spicule is derived from the bee sponge Haliclona sp., and the sponge spicule is a bee sponge spicule (SHS).
[0014] Preferably, the cation of the ionic liquid is derived from at least one of matrine, choline or triisopropanolamine, and the anion of the ionic liquid is derived from at least one of an organic acid such as a C5-C12 fatty acid or glycine.
[0015] Preferably, the C5-C12 fatty acid includes at least one of capric acid, geranic acid, sorbic acid, caproic acid, isovaleric acid, n-octanoic acid or dimethyl acrylic acid.
[0016] Preferably, the ionic liquid comprises at least one of choline caproate, choline isovaleric acid, choline dimethacrylate, choline sorbic acid, choline geranic acid (CAGE), choline glycine, triisopropanolamine n-octanoate, matrine decanoate, or matrine geranic acid. More preferably, the ionic liquid is matrine decanoate or matrine geranic acid.
[0017] In a specific embodiment, the ionic liquid is prepared by the following method: a first raw material corresponding to the cation of the ionic liquid and a second raw material corresponding to the anion of the ionic liquid are subjected to an acid-base neutralization reaction to obtain a biologically active ionic liquid. The first raw material is, for example, matrine, choline, or triisopropanolamine, and the second raw material is, for example, an organic acid, specifically glycine or a C5-C12 fatty acid, such as capric acid, geranic acid, sorbic acid, hexanoic acid, isovaleric acid, n-octanoic acid, or dimethylacrylic acid.
[0018] The second technical solution adopted by the present invention to solve the technical problem is:
[0019] An active composition comprises an active ingredient and the above-mentioned penetration-enhancing composition, that is, the active composition comprises the active ingredient, sponge spicules and ionic liquid.
[0020] In a specific embodiment, the active composition is composed of the active ingredient and the penetration-enhancing composition, that is, the active composition is composed of the active ingredient, sponge spicules and ionic liquid. Further, the sponge spicules in the active composition can be the first component.
[0021] Preferably, the active composition comprises an ionic liquid containing the active ingredient (e.g., the active ingredient is dispersed or dissolved in the ionic liquid) and the sponge spicule. Furthermore, the sponge spicule can be the first component, and the ionic liquid containing the active ingredient can be the second component. Furthermore, the sponge spicule and the ionic liquid containing the active ingredient can be used simultaneously. Furthermore, the ionic liquid containing the active ingredient can be the first component, and the sponge spicule can be the second component. That is, the order in which the components of the active composition are used is not limited, but the effect is better if the sponge spicule is used first to open the channel in the skin, followed by the use of the ionic liquid containing the active ingredient.
[0022] Preferably, the active ingredient is lipophilic.
[0023] In a specific embodiment, the active composition is prepared by the following method: dissolving the active ingredient in the ionic liquid to obtain an ionic liquid containing the active ingredient; combining the sponge spicule with the ionic liquid containing the active ingredient to obtain the active composition.
[0024] The third technical solution adopted by the present invention to solve the technical problem is:
[0025] A method for preparing an active composition, comprising:
[0026] 1) Synthesis of biologically active ionic liquids;
[0027] 2) fully dissolving the active ingredient in the ionic liquid to obtain an ionic liquid containing the active ingredient;
[0028] 3) preparing a sponge spicule solution;
[0029] 4) combining the sponge spicule solution with the ionic liquid containing the active ingredient to obtain the active composition.
[0030] The fourth technical solution adopted by the present invention to solve the technical problem is:
[0031] Application of the above-mentioned penetration-enhancing composition in the preparation of percutaneous absorption preparations.
[0032] The fifth technical solution adopted by the present invention to solve the technical problem is:
[0033] Use of the above active composition in preparing percutaneous absorption preparations.
[0034] In the present invention, the sponge spicule is in the form of a solid sponge spicule or a sponge spicule solution. The sponge spicule solution can be prepared by the following method: adding a certain amount of a buffer solution (for example, a PBS phosphate buffer solution with a molar concentration of 0.01 to 0.2 M and a pH of 6.5 to 7.5), deionized water, physiological saline, or double distilled water, or other solvent that is non-irritating to the skin, to the sponge spicule to obtain a sponge spicule solution. The concentration of the sponge spicule in the sponge spicule solution can be 0.001 to 1000 mg / mL, for example, 0.01 to 500 mg / mL, for example, 0.1 to 200 mg / mL, particularly 1 to 150 mg / mL, specifically 50 to 120 mg / mL, and more specifically 100 mg / mL.
[0035] The active ingredient of the present invention may also be referred to as an effective ingredient, which may be a monomeric compound that can be represented by a molecular formula and a structural formula and has a certain melting point, boiling point, optical rotation, solubility and other physical and chemical constants, or a mixture of two or more of the monomeric compounds. The active ingredient may be derived from plants, animals, microorganisms, etc., or may be artificially synthesized. Furthermore, the active ingredient may be a pharmaceutical active ingredient, or may be a cosmetic active ingredient, or may be a combination of a pharmaceutical active ingredient and a cosmetic active ingredient. The pharmaceutical active ingredient refers to a substance that has pharmacological activity or other direct effects or affects the function or structure of the body in the diagnosis, treatment, symptom relief, symptom management or prevention of a disease. The cosmetic active ingredient refers to a substance that can specifically solve skin problems (such as playing the role of acne removal, anti-wrinkle, anti-aging, whitening, moisturizing, etc.).
[0036] The percutaneous absorption preparation described in the present invention refers to a product that can ultimately be provided to the user. Furthermore, the percutaneous absorption preparation can be a percutaneous absorption pharmaceutical preparation or a percutaneous absorption cosmetic preparation. The percutaneous absorption pharmaceutical preparation refers to a pharmaceutical product that can ultimately be provided to the user, produced by directly using a pharmaceutically acceptable process, or by combining the percutaneous absorption composition or the active composition with at least one pharmaceutically acceptable excipient and using a pharmaceutically acceptable process. For example, when the active composition of the present invention includes a pharmaceutical active ingredient, the active composition can be used to prepare a percutaneous absorption pharmaceutical preparation. The percutaneous absorption cosmetic preparation refers to a cosmetic product that can ultimately be provided to the user, produced by directly using a cosmetically acceptable process, or by combining the percutaneous absorption composition or the active composition with at least one cosmetically acceptable excipient and using a cosmetically acceptable process. For example, when the active composition of the present invention includes a cosmetic active ingredient, the active composition can be used to prepare a percutaneous absorption cosmetic preparation. The term "acceptable" refers to compliance with the requirements of all normative documents, such as relevant laws and regulations.
[0037] Unless otherwise specified, the equipment, reagents, processes, parameters, etc. involved in the present invention are conventional equipment, reagents, processes, parameters, etc. and are not given as examples.
[0038] All ranges recited herein include all points within the range.
[0039] In the present invention, the "room temperature" refers to the normal ambient temperature, which can be 10-30°C.
[0040] The penetration-enhancing composition of the present invention can promote the percutaneous absorption of active ingredients. The active ingredients in the active composition of the present invention can be effectively absorbed percutaneously, especially when the active ingredient is a sparingly soluble substance (e.g., a substance that is sparingly soluble in water, physiological saline, glucose solution, buffer, or ethanol, or a non-toxic or low-toxic organic solvent, such as a lipophilic substance). These sparingly soluble substances do not have a suitable solvent in the current technology to dissolve them and can be used for skin administration. Although there are some organic solvents that can dissolve these substances in appropriate amounts, such organic solvents are very irritating to the skin and cannot be directly applied to the skin. Therefore, in the current technology, these sparingly soluble substances cannot be placed on the skin in a solution state for administration, and the solution state is an important condition for bone needles to achieve percutaneous delivery alone. Therefore, using bone needles alone cannot deliver these sparingly soluble substances.
[0041] The main technical concept of the present invention is to utilize ionic liquids to improve the solubility of poorly soluble active ingredients, using bioactive ionic liquids as green solvents to increase the solubility of poorly soluble active ingredients to form a solution. Then, by applying the solution of the poorly soluble active ingredient to sponge spicules, the microchannels formed by the sponge spicules acting on the skin are utilized to effectively increase the transdermal absorption of the poorly soluble active ingredient. Therefore, depending on the solubility characteristics of different poorly soluble active ingredients, different types of ionic liquids can be selected to form solutions with higher solubility, and combined with sponge spicules to achieve transdermal absorption, and the ionic liquids listed in the present invention are not limited to them.
[0042] In a specific embodiment, the technical solution of the present invention includes the following steps:
[0043] (1) Synthesis of ionic liquids: Synthesis of ionic liquids with biological activity;
[0044] (2) Measuring the solubility of poorly soluble active ingredients: Weigh an excess of the poorly soluble active ingredient in the ionic liquid, and measure its solubility in the ionic liquid after it is fully dissolved;
[0045] (3) Measuring the cytotoxicity of ionic liquids: Human keratinocytes HaCat were selected and the cytotoxicity of ionic liquids on HaCat cells was measured using the MTT assay;
[0046] (4) Preparing an ionic liquid solution of a poorly soluble active ingredient: fully dissolving the poorly soluble active ingredient in the ionic liquid to obtain an ionic liquid solution containing the active ingredient at a certain concentration;
[0047] (5) Preparation of sponge spicule solution: Prepare a sponge spicule solution with a concentration of 100 mg / mL using a certain amount of buffer or deionized water;
[0048] (6) Combined skin administration: Apply the sponge spicule solution obtained in step (4) to clean skin, and then apply the ionic liquid solution containing the active ingredient.
[0049] In a preferred embodiment of the present invention, step (1) comprises: selecting matrine, choline and triisopropanolamine as cations, selecting capric acid, geranic acid, sorbic acid, hexanoic acid, isovaleric acid, n-octanoic acid and dimethylacrylic acid as organic anions, mixing them in a certain proportion, and obtaining a biologically active ionic liquid through an acid-base neutralization reaction.
[0050] In a preferred embodiment of the present invention, step (2) is: weighing an excess of the poorly soluble active ingredient into 1 g of ionic liquid, water, ethanol and water / ethanol (1:1), stirring and mixing evenly, and then fully dissolving the active ingredient by ultrasonic irradiation to obtain a saturated solution of the poorly soluble active ingredient, and then measuring the solubility of the poorly soluble active ingredient by a microplate reader.
[0051] In a preferred embodiment of the present invention, step (3) comprises culturing HaCat cells and preparing ionic liquid solutions of different concentrations: 10 mg / mL, 8 mg / mL, 6 mg / mL, 5 mg / mL, 4 mg / mL, 3 mg / mL, 2 mg / mL, and 1 mg / mL. The survival rates of HaCat cells at different ionic liquid concentrations are determined using the MTT assay, and the IC50 values of the ionic liquids are calculated.
[0052] In a preferred embodiment of the present invention, step (4) is: weighing a certain amount of the poorly soluble active ingredient and the ionic liquid, then adding the poorly soluble active ingredient to the ionic liquid, stirring and mixing evenly, and then subjecting the mixture to ultrasonic irradiation so that the active ingredient is fully dissolved in the ionic liquid to obtain an ionic liquid solution of the poorly soluble active ingredient with a certain concentration.
[0053] In a preferred embodiment of the present invention, step (5) is: adding a certain amount of a solvent with no skin irritation, such as PBS phosphate buffer, deionized water, physiological saline or double distilled water, with a molar concentration of 0.01 to 0.2 M and a pH of 6.5 to 7.5, to the sponge spicules to make the concentration of the sponge spicules 100 mg / mL, to obtain a sponge spicule solution.
[0054] In a preferred embodiment of the present invention, step (6) is: applying the sponge spicule solution directly to the cleaned skin, and massaging it electrically or manually for a certain time, for example, 0.5 to 10 minutes, or 1 to 5 minutes, specifically for example, 2 minutes, and washing the massaged area with PBS, deionized water, physiological saline, etc. to wash away the sponge spicules remaining on the skin, and then applying the ionic liquid solution containing the active ingredient to the skin after the spicule massage.
[0055] Compared with the background technology, this technical solution has the following advantages:
[0056] The ionic liquid used in the present invention is used as a cosolvent for poorly soluble active ingredients. Compared with traditional organic solvents, it has lower toxicity, is more environmentally friendly and bio-friendly, and can significantly increase the solubility of poorly soluble active ingredients. The synthesis method of ionic liquids is simple, convenient and easy to obtain, and can effectively increase the solubility of poorly soluble active ingredients. In addition, a large number of past studies have also confirmed that ionic liquids are also good chemical penetration enhancers. The present invention innovatively combines "ionic liquids" and "sponge spicules" into a transdermal drug delivery system, using ionic liquids to enhance the solubility of poorly soluble active ingredients, and then using sponge spicules to open the microchannels of the skin, allowing the active ingredients to enter the deep layers of the skin, thereby solving the difficulty of transdermal delivery of poorly soluble active ingredients. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Figure 1 shows the appearance of the ionic liquid finally synthesized in Example 1, which includes, from left to right, choline caproate, choline isovaleric acid, choline dimethacrylate, choline sorbic acid, choline geranic acid (CAGE), choline glycine, triisopropanolamine n-octanoate, matrine capric acid, and matrine geranic acid.
[0058] FIG2 shows the solubility of coumarin-6 in different ionic liquids in Example 2.
[0059] FIG3 shows the cytotoxicity results of the ionic liquid in Example 3 on human keratinocytes HaCat.
[0060] Figure 4 is a comparison of the absorption amounts of the ionic liquid group of coumarin-6 (CAGE, matrine decanoic acid, matrine geranic acid, choline hexanoic acid, triisopropanolamine n-octanoate, choline dimethacrylate) and the sponge spicule-ionic liquid group (SHS-CAGE, SHS-matrine decanoic acid, SHS-matrine geranic acid, SHS-choline hexanoic acid, SHS-triisopropanolamine n-octanoate, SHS-choline dimethacrylate) in each cortical layer in Example 4. In the figure, the groups from left to right are CAGE, SHS-CAGE, matrine decanoic acid, SHS-matrine decanoic acid, matrine geranic acid, SHS-matrine geranic acid, choline hexanoic acid, SHS-choline hexanoic acid, triisopropanolamine n-octanoate, SHS-triisopropanolamine n-octanoate, choline dimethacrylate, and SHS-choline dimethacrylate.
[0061] Figure 5 is a comparison of the total skin absorption of the ionic liquid group (CAGE, matrine decanoate, matrine geranyl acid, choline hexanoate, triisopropanolamine n-octanoate, choline dimethacrylate) and the sponge spicule-ionic liquid group (SHS-CAGE, SHS-matrine decanoate, SHS-matrine geranyl acid, SHS-choline hexanoate, SHS-triisopropanolamine n-octanoate, SHS-choline dimethacrylate) of coumarin-6 in Example 4.
[0062] Figure 6 is a comparison of the absorption results of the ionic liquid group (CAGE, matrine decanoate, matrine geranic acid) of coumarin-6 in each cortical layer, the roller microneedle-ionic liquid group (roller microneedle-CAGE, roller microneedle-matrine decanoate, roller microneedle-matrine geranic acid) and the sponge bone needle-ionic liquid group (SHS-CAGE, SHS-matrine decanoate, SHS-matrine geranic acid) in Example 5. The groups from left to right in the figure are CAGE, roller microneedle-CAGE, SHS-CAGE, matrine decanoate, roller microneedle-matrine decanoate, SHS-matrine decanoate, matrine geranic acid, roller microneedle-matrine geranic acid, and SHS-matrine geranic acid.
[0063] Figure 7 is a comparison of the total skin absorption of coumarin-6 in Example 5 in the ionic liquid group (CAGE, matrine decanoate, matrine geranic acid), the roller microneedle-ionic liquid group (roller microneedle-CAGE, roller microneedle-matrine decanoate, roller microneedle-matrine geranic acid) and the sponge bone needle-ionic liquid group (SHS-CAGE, SHS-matrine decanoate, SHS-matrine geranic acid).
[0064] Figure 8 shows confocal images of the total skin absorption of coumarin-6 in the ionic liquid, microneedle roller-ionic liquid, and sponge bone needle-ionic liquid groups in Example 5. Images numbered ai correspond to: a: microneedle roller + matrine geranyl acid group, b: matrine geranyl acid group, c: matrine decanoate group, d: microneedle roller + matrine decanoate group, e: microneedle roller + CAGE group, f: CAGE group, g: SHS + matrine geranyl acid group, h: SHS + CAGE group, and i: SHS + matrine decanoate group.
[0065] Figure 9 is a comparison of the absorption amounts of protoporphyrin IX in each cortical layer in the ionic liquid group (CAGE, matrine decanoate, matrine geranic acid), the roller microneedle-ionic liquid group (roller microneedle-CAGE, roller microneedle-matrine decanoate, roller microneedle-matrine geranic acid), and the sponge bone needle-ionic liquid group (SHS-CAGE, SHS-matrine decanoate, SHS-matrine geranic acid) in Example 6. The groups from left to right in the figure are CAGE, roller microneedle-CAGE, SHS-CAGE, matrine decanoate, roller microneedle-matrine decanoate, SHS-matrine decanoate, matrine geranic acid, roller microneedle-matrine geranic acid, and SHS-matrine geranic acid.
[0066] Figure 10 is a comparison of the total skin absorption of protoporphyrin IX in Example 6 in the ionic liquid group (CAGE, matrine decanoate, matrine geranic acid), the roller microneedle-ionic liquid group (roller microneedle-CAGE, roller microneedle-matrine decanoate, roller microneedle-matrine geranic acid) and the sponge bone needle-ionic liquid group (SHS-CAGE, SHS-matrine decanoate, SHS-matrine geranic acid).
[0067] Figure 11 shows confocal images of the total skin absorption of protoporphyrin IX in the ionic liquid, micro-roller-ionic liquid, and sponge bone needle-ionic liquid groups in Example 6. Images numbered ai correspond to: a, matrine decanoate group; b, micro-roller + matrine decanoate group; c, matrine geranyl group; d, micro-roller + CAGE group; e, micro-roller + matrine geranyl group; f, CAGE group; g, SHS + matrine decanoate group; h, SHS + matrine geranyl group; and i, SHS + CAGE group. DETAILED DESCRIPTION
[0068] The present invention will be further described below with reference to the accompanying drawings and examples.
[0069] Example 1
[0070] The preparation method of the ionic liquid of this embodiment comprises the following steps:
[0071] (1) Preparation of choline fatty acid ionic liquids (choline hexanoate, choline isovalerate, choline dimethacrylate, choline sorbate, CAGE)
[0072] At room temperature, an equimolar solution of choline bicarbonate is slowly added to an equimolar solution of an organic acid (caproic acid, isovaleric acid, dimethylacrylic acid, sorbic acid, geranic acid) (if the organic acid is solid at room temperature, dissolve the organic acid in an appropriate amount of anhydrous ethanol to prepare an organic acid solution for use), stirring while adding. CO2 gas is generated during the stirring process until no more gas is generated. The mixture is then placed in a rotary evaporator at 60°C, 100 rpm, and rotary evaporated for 2 hours to remove the solvent. The resulting product is placed in a vacuum drying oven and vacuum dried at 60°C for 48 hours to obtain a choline-based ionic liquid. Finally, it is placed in a drying dish and stored in a cool, dark environment for later use. See Figure 1.
[0073] (2) Preparation of choline glycine ionic liquid
[0074] Dissolve glycine in an appropriate amount of water to obtain a glycine aqueous solution. Slowly add an equimolar amount of choline hydroxide solution to the glycine solution in an ice-water bath while stirring. Allow to react in the ice-water bath for 48 hours. The mixture is then placed in a rotary evaporator at 60°C, 100 rpm, and the solvent is removed for 2 hours. The resulting product is placed in a vacuum drying oven at 60°C and vacuum-dried for 48 hours to obtain a cholineglycine ionic liquid. Finally, place in a desiccating dish and store in a cool, dark environment until ready for use. See Figure 1.
[0075] (3) Preparation of triisopropanolamine octanoate ionic liquid
[0076] Weigh equal moles of octanoic acid and triisopropanolamine into a 50 mL beaker, mix thoroughly, incubate in an 80°C water bath overnight, then mix again and ultrasonically irradiate for 30 minutes to obtain the triisopropanolamine octanoate ionic liquid. The resulting product was vacuum-dried in a vacuum oven at 60°C for 48 hours to remove any moisture. Finally, place in a desiccating dish and store in a cool, dark environment until ready for use. See Figure 1.
[0077] (4) Preparation of matrine-based ionic liquids (matrine decanoate and matrine geranate)
[0078] Equimolar matrine and fatty acids (capric acid, geranic acid) were dissolved in anhydrous ethanol (nitrogen was passed through for 10 minutes before use to remove the air in the ethanol), and then the matrine solution was slowly added to the fatty acid solution while stirring. The mixture was then stirred for 24 hours in a nitrogen atmosphere at room temperature to allow matrine and fatty acids to fully react. The mixture was then placed in a rotary evaporator at 60°C, 100rpm, and rotary evaporated for 2 hours to remove the solvent. The obtained product was placed in a vacuum drying oven and vacuum dried at 60°C for 48 hours to obtain a matrine fatty acid ionic liquid. Finally, it was placed in a drying dish and stored in a cool, dark environment for later use. See Figure 1.
[0079] Example 2
[0080] This embodiment measures the solubility of poorly soluble drugs, comprising the following steps:
[0081] (1) Using coumarin-6 as a model drug, the solubility of coumarin-6 in different ionic liquids (choline hexanoate, choline isovaleric acid, choline dimethacrylate, choline sorbic acid, CAGE, choline glycine, triisopropanolamine octanoate, matrine decanoate, and matrine geranyl acid) was measured. An excess of coumarin-6 was weighed and added to 1 g of ionic liquid, stirred evenly, and then ultrasonically irradiated for 1 hour to allow the drug to fully dissolve. Centrifuged at 10000 rpm for 10 minutes, the supernatant was the saturated solution of the drug in the ionic liquid. A multifunctional microplate reader was used to read the solubility of coumarin-6 in different ionic liquids according to the detection wavelength (excitation wavelength: 466 nm and emission wavelength: 504 nm). Referring to Figure 2, the results show that all ionic liquids have a certain dissolving effect on coumarin-6. The solubility in choline fatty acids is generally low. The ionic liquid with the lowest solubility is choline isovaleric acid, at only 0.06 mg / g; the highest is choline geranic acid, at 0.44 mg / g. Its solubility in choline glycine is 0.5 mg / g. The solubility of triisopropanolamine octanoate for coumarin-6 is 1.38 mg / g, higher than that of choline-based ionic liquids. Matrine decanoate and matrine geranic acid have the best solubilization effects on coumarin-6, at 21.67 mg / g and 10.30 mg / g, respectively, an order of magnitude higher than other ionic liquids.
[0082] (2) Matrine decanoate and matrine geranyl acid, which have the best solubilization effect, were selected to investigate their solubilization effect on the poorly soluble drugs PpIX and Nile red. Since CAGE is currently the ILs with the best permeation-enhancing effect, the solubility of CAGE on PpIX and Nile red was also tested. Excess drugs were weighed and added to 1g of water, anhydrous ethanol, water / anhydrous ethanol (1:1), CAGE, matrine decanoate and matrine geranyl acid. After stirring evenly, the mixture was ultrasonically irradiated for 1h to allow the drugs to fully dissolve. The mixture was centrifuged at 10000rpm for 10min, and the supernatant was the saturated solution of the drug. The solubility of the poorly soluble drugs in different solutions was read using a multifunctional microplate reader according to the detection wavelengths of protoporphyrin IX (excitation wavelength: 409nm and emission wavelength: 633nm) and Nile red (excitation wavelength: 555nm and emission wavelength: 636nm). The results showed that ionic liquids can significantly improve the solubility of poorly soluble drugs. Referring to attached table 1, the solubility of the three fat-soluble drugs of coumarin-6, protoporphyrin IX and Nile red in water, absolute ethanol, water / absolute ethanol (1: 1), CAGE, matrine decanoate and matrine geranic acid in Example 2 is shown. The results show that ionic liquids have a solubilizing effect on poorly soluble drugs, wherein the solubilizing effect of CAGE is slightly poor, and the solubilizing effects of the two ILs of matrine-based matrine decanoate and matrine geranic acid are very good, and the solubilizing effect on poorly soluble drugs is far superior to absolute ethanol. However, it should be noted that this does not mean that the ionic liquid of the present invention can only select matrine decanoate and matrine geranic acid. In practical applications, according to the solubility characteristics of different poorly soluble drugs, different ionic liquids can be selected to dissolve, and as long as a solution with good solubility can be made, the purpose of the present invention can be achieved.
[0083] Table 1 Solubility of fat-soluble drugs in different solvents (μg / g)
[0084] Example 3
[0085] The method for detecting the cytotoxicity of ionic liquids in this embodiment comprises the following steps:
[0086] 1. Cell culture
[0087] 1) Cell recovery
[0088] (1) Take out DMEM complete medium from the 4°C refrigerator and place it in a 37°C constant temperature water bath for 30 minutes;
[0089] (2) Remove the frozen HaCat cells from liquid nitrogen and quickly place them in a 37°C constant temperature water bath. Gently shake them to thaw until there are no crystals in the cryotube. Then wipe the outer wall of the cryotube with 75% alcohol.
[0090] (3) Take 5 mL of complete culture medium and place it in a 15 mL centrifuge tube. Transfer the thawed cell suspension in (2) to the centrifuge tube and centrifuge at 1000 rpm for 5 min.
[0091] (4) Discard the supernatant, resuspend the pellet in 10 mL of complete culture medium, inoculate into a cell culture dish (d = 10 cm), and culture in a cell culture incubator at 37°C and 5% CO2;
[0092] (5) The next day, fresh complete culture medium was used to continue the culture.
[0093] 2) Cell culture medium replacement
[0094] (1) Take out the cell culture dish from the incubator and remove the old complete culture medium in the dish;
[0095] (2) Add 3 mL of sterile 0.01 M PBS solution and gently shake to wash the cells to remove dead cells;
[0096] (3) Add 10 mL of fresh complete culture medium to the culture dish and continue to culture in the cell culture incubator.
[0097] 3) Cell passaging
[0098] (1) When the cells grow to cover 80% of the culture dish, remove the cell culture medium in the culture dish;
[0099] (2) Add 3 mL of sterile 0.01 M PBS solution and gently shake to wash the cells twice;
[0100] (3) Add 1 mL of 0.25% trypsin digestion solution to the culture dish and digest for 4–5 min. Observe under a microscope. When the cells shrink and become round, add 5 mL of complete culture medium to terminate the digestion.
[0101] (4) Gently pipette the cells to dislodge them, then transfer the suspension to a 15 mL centrifuge tube and centrifuge at 1000 rpm for 5 min.
[0102] (5) Discard the supernatant and resuspend the precipitated cells in 2 mL of complete culture medium. Then, subculture them at a ratio of 1:4 (4 culture dishes). Add new complete culture medium to 10 mL and pipette several times to disperse the cells evenly in the culture dish. Finally, culture the cells in a 37°C, 5% CO2 cell culture incubator. Change the medium every 1 to 2 days.
[0103] 4) Cell cryopreservation
[0104] (1) When the cells have grown to cover 80% of the culture dish, collect the cells by centrifugation according to the cell digestion method in "Cell Passaging" (steps (1) to (4));
[0105] (2) Discard the supernatant, add 1 mL of serum-free freezing solution to the pelleted cells, mix well, and add to the cryopreservation tube;
[0106] (3) Place the cryovials in a -80°C freezer for 24 hours and then transfer to a liquid nitrogen tank for long-term storage.
[0107] 2. MTT assay to detect the toxic effects of ionic liquids on cells
[0108] (1) Collect logarithmic phase cells and adjust the cell suspension concentration to 5×10 4 cell / mL, and divided into 96-well plates, adding 200 μL of cell suspension to each well. Then, add sterile PBS solution to the wells around the 96-well plate to slow down evaporation, and finally incubate in a cell culture incubator for 24 hours;
[0109] (2) Preparation of ionic liquid solutions of different concentrations
[0110] Accurately weigh 10 mg of ionic liquid (CAGE, matrine decanoate, and matrine geranate), dissolve it in 1 mL of complete culture medium, and then filter with a 0.22 μm filter membrane to remove impurities such as bacteria. This mother solution is added to fresh complete culture medium to make the final concentrations of the ionic liquids: 10 mg / mL, 8 mg / mL, 6 mg / mL, 5 mg / mL, 4 mg / mL, 3 mg / mL, 2 mg / mL, and 1 mg / mL, respectively.
[0111] (3) Remove the old culture medium from the 96-well plate, then add 100 μL of the ionic liquid solution of different concentrations prepared in (2), set up control wells (cells, complete culture medium, MTT, Formazan solution), set up zero wells (complete culture medium, MTT, Formazan solution), and set up 5 replicate wells for each group; then place the cells in an incubator and incubate for 24 hours;
[0112] (4) Carefully remove the supernatant, add 90 μL of fresh culture medium, and then add 10 μL of MTT solution, and continue incubation for 4 h;
[0113] (5) Then carefully aspirate the supernatant (be careful not to aspirate the purple crystalline substance at the bottom) and add 110 μL of Formazan solution to each well;
[0114] (6) Place the 96-well plate on a shaker and shake at low speed for 10 min to fully dissolve the purple crystalline substance. Finally, use a microplate reader to measure the absorbance of each well at 490 nm.
[0115] (7) Calculate the cell survival rate at different IL concentrations, and use GraphPad Prism 8.0.2 software to calculate the IC50 value of IL for HaCat cells.
[0116] The toxicity of three interleukins (ILs)—CAGE, matrine decanoate, and matrine geranyl acid—on immortalized human epidermal HaCat cells was determined using the MTT assay. As shown in Figure 3, the results show that the toxicity of the three ILs toward HaCat cells gradually increased with increasing concentration, but ILs with different anion and cation combinations had distinct effects on cell viability. The IC50 values of the ILs were calculated by fitting the cell survival rates at different IL concentrations. CAGE was the least toxic IL toward HaCat cells, with an IC50 value of 3.06 mg / mL. Matrine geranyl acid and matrine decanoate had slightly higher IC50 values than CAGE, at 2.66 mg / mL and 1.95 mg / mL, respectively. A large number of experiments have demonstrated the safety of CAGE in transdermal drug delivery systems. Although the cytotoxicity of matrine decanoate and matrine geranate is slightly greater than that of CAGE, compared with the solubility results of ionic liquids for fat-soluble drugs in Example 2, the solubility of matrine-based ionic liquids for fat-soluble drugs is much higher than that of CAGE. This means that in actual use, the amount of matrine-based ionic liquid used will be less than that of CAGE, so the actual toxicity produced will also be less than that of CAGE. Therefore, matrine-based ionic liquids can also be safely used in transdermal drug delivery systems.
[0117] Example 4
[0118] The method of co-delivering coumarin-6 by combining ionic liquid with sponge spicules in this embodiment includes the following steps:
[0119] (1) Preparation of poorly soluble drug ionic liquid solution: Weigh 1.5 mg of coumarin-6 and add it to 10 g of CAGE, matrine decanoate, matrine geranyl acid, choline hexanoate, choline dimethacrylate, and triisopropanolamine octanoate ionic liquid. Then stir manually for 10 min to uniformly dissolve coumarin-6 in the ionic liquid. Ultrasonic irradiation is performed for 30 min. Repeat the above steps once until coumarin-6 is completely dissolved to obtain a coumarin-6 ionic liquid solution. Store in a refrigerator at 4°C away from light until use.
[0120] (2) Preliminary treatment of pig skin: Take fresh pig skin, remove the subcutaneous fat layer, shave the pig hair to a length of no longer than 2 mm, and use it immediately or freeze it at -20℃~-80℃ for later use.
[0121] (3) Preparation of bee sponge spicule (SHS) solution: Add a certain amount of PBS phosphate buffer solution with a molar concentration of 0.01-0.2 M and a pH of 6.5-7.5, deionized water, physiological saline or double distilled water, etc., which are non-irritating to the skin, to the sponge spicules so that the mass concentration of the sponge spicules reaches 100 mg / mL to obtain the sponge spicule solution.
[0122] (4) In vitro transdermal test: Pig skin of the same diameter was drilled with a circular punch and mounted on a Franz diffusion transdermal apparatus. An in vitro transcutaneous resistance test was used to measure changes in skin conductivity before and after the application of the sponge spicule solution. Before the application of the sponge spicule, the conductivity of the in vitro pig skin was no higher than 10 μA, indicating that the skin's stratum corneum barrier function was intact and could be used for subsequent experiments. After the application of the sponge spicule, the conductivity of the in vitro pig skin increased to 150 μA, indicating that the skin's stratum corneum barrier was destroyed by the sponge spicule and the skin channels were opened. 0.15 g of a 150 μg / g coumarin-6 / ionic liquid solution was added to the pig skin that had not been massaged with the spicules and the pig skin that had been massaged with the spicules, respectively, so that the drug solution was evenly covered on the skin surface. The skin was removed after 16 hours of transdermal application at 37°C and 600 r / min.
[0123] Using tape stripping, the stratum corneum layers 1 to 10 were sequentially exfoliated, the viable epidermis was isolated, and the dermis was partially minced. Each layer was immersed in 4 mL of methanol and extracted at 180 rpm for 20 hours at room temperature. A multifunctional microplate reader was used to read the absorption of coumarin-6 in the stratum corneum, viable epidermis, dermis, and receiving cell, using the coumarin-6 detection wavelength. The results showed that the ionic liquid had a certain permeation-enhancing effect on coumarin-6, allowing it to reach deeper layers of the skin, primarily accumulating in the epidermis and dermis (see Figure 4). Furthermore, the combined application of sponge spicules and ionic liquid significantly enhanced the transdermal penetration of coumarin-6, allowing it to reach deeper layers of the skin (see Figures 4 and 5).
[0124] Example 5
[0125] The method of co-delivering coumarin-6 by combining ionic liquid with roller microneedles or sponge bone needles in this embodiment includes the following steps:
[0126] (1) Preparation of poorly soluble drug ionic liquid solution: Similar to Example 4, 1.5 mg of coumarin-6 was weighed and dissolved in 10 g of CAGE, matrine decanoate and matrine geranate ionic liquid solutions to prepare a coumarin-6 / ionic liquid solution with a concentration of 150 μg / g.
[0127] (2) Preliminary treatment of pigskin: same as in Example 4.
[0128] (3) Preparation of bee sponge spicule solution: same as Example 4.
[0129] (4) In vitro transdermal quantitative experiment: Similar to Example 4. After the roller microneedle action, the conductivity of the isolated pig skin increased to 100μA, indicating that the skin stratum corneum barrier was destroyed by the roller and the skin channels were opened. 0.15g of 150μg / g coumarin-6 / ionic liquid solution was added to the pig skin without bone needle massage, roller microneedle massage and bone needle massage, respectively, so that the drug solution was evenly covered on the skin surface. At 37℃, 600r / min, the pig skin was removed after 16h of transdermal application. The results showed that the combined application of ionic liquid and sponge bone needle significantly increased the transdermal rate of coumarin-6, while the combined application of ionic liquid and roller microneedle did not significantly increase the transdermal rate of coumarin-6. See Figures 6 and 7.
[0130] (5) In vitro transdermal qualitative experiment: Use confocal microscopy to detect the penetration of coumarin-6 into the skin. Take the pig skin that has not been peeled off after transdermal treatment, and use a 5mm diameter punch to knock out a piece of pig skin. Place the knocked pig skin in a freezing embedding box, add OCT for embedding, and then freeze it in a -80℃ refrigerator. Use a freezing microtome to cut the frozen pig skin into slices with a thickness of 20μm. Adsorb the slices on a glass slide, add neutral resin, and cover with a cover glass to seal. Finally, use a confocal microscope to take pictures to observe the penetration of coumarin-6 into the pig skin. See Figure 8.
[0131] Example 6
[0132] The method of co-delivering protoporphyrin IX using an ionic liquid in combination with a roller microneedle or a sponge bone needle in this embodiment includes the following steps:
[0133] (1) Preparation of poorly soluble drug ionic liquid solution: Similar to Example 5, 2.5 mg of protoporphyrin IX was weighed and dissolved in 10 g of CAGE, matrine decanoate, and matrine geranate ionic liquid solutions to prepare a protoporphyrin IX / ionic liquid solution with a concentration of 250 μg / g.
[0134] (2) Preliminary treatment of pigskin: same as in Example 5.
[0135] (3) Preparation of bee sponge spicule solution: same as Example 5.
[0136] (4) In vitro transdermal quantitative experiment: Similar to Example 5. 0.2 g of 250 μg / g protoporphyrin IX / ionic liquid solution was added to pig skin that had not been subjected to bone needle massage, roller microneedle massage, and bone needle massage, respectively, so that the drug solution was evenly covered on the skin surface. The pig skin was removed after 16 hours of transdermal perfusion at 37°C and 600 r / min. A multifunctional microplate reader was used to read the absorption of coumarin-6 in the stratum corneum, viable epidermis, dermis, and receiving pool according to the detection wavelength of protoporphyrin IX. The results showed that the ionic liquid had a small effect on the penetration of protoporphyrin IX, and protoporphyrin IX could only reach the epidermis. However, after the ionic liquid was used in conjunction with the sponge bone needle, the transdermal depth and transdermal rate of protoporphyrin IX were greatly improved. In contrast, after the ionic liquid was used in conjunction with the roller microneedle, the transdermal rate of protoporphyrin IX was not significantly increased. See Figures 9 and 10.
[0137] (5) In vitro permeation qualitative experiment: Similar to Example 5, a confocal microscope was used to detect the penetration of protoporphyrin IX into the skin. See Figure 11.
[0138] The above description is merely a preferred embodiment of the present invention and therefore cannot be used to limit the scope of the present invention. In other words, equivalent changes and modifications made according to the scope of the present invention and the contents of the specification should still fall within the scope of the present invention. Industrial Applicability
[0139] The present invention discloses a penetration-enhancing composition of an ionic liquid and sponge spicules, its active composition, and its application. This invention belongs to the field of pharmaceutical technology, specifically relating to the synthesis and application of ionic liquids and their transdermal delivery. The present invention synthesizes several bioactive ionic liquids. These green solvents exhibit good solubility for poorly soluble active ingredients. When used in combination with sponge spicules, the synergistic effect of the ionic liquids and sponge spicules enhances the transdermal delivery of lipophilic substances, significantly promoting the transdermal delivery of poorly soluble active ingredients. This method has industrial applicability.
Claims
1. A penetration-enhancing composition, characterized in that: The penetration-enhancing composition comprises sponge spicules and ionic liquid.
2. The penetration-promoting composition according to claim 1, characterized in that: The sponge spicules are derived from the bee sponge Haliclona sp., and the sponge spicules are bee sponge spicules.
3. The penetration-promoting composition according to claim 1, characterized in that: The cation of the ionic liquid is derived from at least one of matrine, choline or triisopropanolamine, and the anion of the ionic liquid is derived from at least one of C5-C12 fatty acid or glycine.
4. The penetration-promoting composition according to claim 3, characterized in that: The C5-C12 fatty acid includes at least one of capric acid, geranic acid, sorbic acid, caproic acid, isovaleric acid, n-octanoic acid or dimethyl acrylic acid.
5. The penetration-enhancing composition according to claim 1, characterized in that: The ionic liquid includes at least one of choline caproate, choline isovaleric acid, choline dimethacrylate, choline sorbic acid, choline geranic acid, choline glycine, triisopropanolamine n-octanoate, matrine capric acid or matrine geranic acid.
6. Use of the penetration-enhancing composition according to any one of claims 1 to 5 in the preparation of a percutaneous absorption preparation.
7. An active composition, characterized in that: The active composition comprises an active ingredient and a penetration-enhancing composition according to any one of claims 1 to 5; 8. The active composition according to claim 7, characterized in that: The active ingredient is lipophilic.
9. The active composition according to claim 7, characterized in that: The active composition consists of an ionic liquid containing the active ingredient and the sponge spicule.
10. Use of the active composition according to claim 7, 8 or 9 in the preparation of a percutaneous absorption preparation.
11. A method for preparing the active composition according to claim 7, 8 or 9, characterized in that: include: 1) Synthesis of ionic liquids; 2) fully dissolving the active ingredient in the ionic liquid to obtain an ionic liquid containing the active ingredient; 3) preparing a sponge spicule solution; 4) combining the sponge spicule solution with the ionic liquid containing the active ingredient to obtain the active composition.
Citation Information
Patent Citations
Application of sponge spicule as skin physical penetration enhancer
CN105999535A
Transdermal absorption composition and application of same to preparation of transdermal absorption preparation
CN109381422A
System for promoting permeation of active ingredients into skin
CN111407721A
Whitening co-loaded ionic liquid type liposome and preparation method thereof
CN114533568A
Ionic liquid and sponge spicule infiltration promoting composition and active composition and application thereof
CN117100681A
